Dianthus Therapeutics
DNTH
DNTH
241 hedge funds and large institutions have $5.36B invested in Dianthus Therapeutics in 2026 Q1 according to their latest regulatory filings, with 98 funds opening new positions, 83 increasing their positions, 54 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
46% more funds holding
Funds holding: 165 → 241 (+76)
29.88% more ownership
Funds ownership: 114.56% → 144.43% (+30%)
12% less call options, than puts
Call options by funds: $19.7M | Put options by funds: $22.3M
Holders
241
Holding in Top 10
16
Calls
$19.7M
Puts
$22.3M
Top Buyers
| 1 | +$122M | |
| 2 | +$77.4M | |
| 3 | +$74.8M | |
| 4 |
BlackRock
New York
|
+$73M |
| 5 |
FAM
Fred Alger Management
New York
|
+$65.3M |
Top Sellers
| 1 | -$38.6M | |
| 2 | -$30.3M | |
| 3 | -$27.6M | |
| 4 |
OCA
Octagon Capital Advisors
New York
|
-$27.2M |
| 5 |
Millennium Management
New York
|
-$23.5M |
